Profile data is unavailable for this security.
About the company
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
- Revenue in USD (TTM)0.00
- Net income in USD-139.65m
- Incorporated2017
- Employees112.00
- LocationBiomea Fusion Inc900 Middlefield Road, 4Th FloorREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 980-9099
- Fax+1 (302) 655-5049
- Websitehttps://www.biomeafusion.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GH Research PLC | -100.00bn | -100.00bn | 337.66m | 49.00 | -- | 1.70 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -69.64m | 339.86m | 164.00 | -- | 1.44 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Climb Bio Inc | 0.00 | -64.20m | 346.03m | 9.00 | -- | 1.55 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 352.79m | 28.00 | -- | 6.89 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 365.95m | 157.00 | -- | 0.5512 | -- | 10.46 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Fate Therapeutics Inc | 12.32m | -175.72m | 366.69m | 181.00 | -- | 0.9235 | -- | 29.77 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
C4 Therapeutics Inc | 29.38m | -107.87m | 373.04m | 145.00 | -- | 1.50 | -- | 12.70 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Biomea Fusion Inc | 0.00 | -139.65m | 379.48m | 112.00 | -- | 3.65 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Voyager Therapeutics Inc | 143.77m | 9.02m | 383.91m | 162.00 | 45.88 | 1.14 | 27.64 | 2.67 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 384.47m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 387.45m | 25.00 | -- | -- | -- | 235.53 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Grail Inc | 109.74m | -2.88bn | 404.57m | 1.37k | -- | 0.1501 | -- | 3.69 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
SAGE Therapeutics Inc | 97.24m | -445.67m | 405.37m | 487.00 | -- | 0.6438 | -- | 4.17 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Organogenesis Holdings Inc | 448.39m | -16.54m | 408.33m | 862.00 | -- | 1.55 | -- | 0.9107 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Taysha Gene Therapies Inc | 12.87m | -114.34m | 411.94m | 52.00 | -- | 3.72 | -- | 32.00 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Prime Medicine Inc | 591.00k | -217.44m | 421.31m | 234.00 | -- | 2.14 | -- | 712.87 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.36m | 14.90% |
Cormorant Asset Management LPas of 12 Jun 2024 | 3.57m | 9.93% |
Laurion Capital Management LPas of 31 Mar 2024 | 2.72m | 7.57% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 2.11m | 5.87% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.66m | 4.62% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.31m | 3.64% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.27m | 3.54% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 1.19m | 3.32% |
Aisling Capital Management LPas of 30 Jun 2024 | 798.76k | 2.22% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 675.74k | 1.88% |